Orforglipron
Research profile · How we handle evidence
Oral non-peptide GLP-1 receptor agonist developed for weight loss and diabetes treatment.
Evidence Score
Moderate confidence
Category
Therapeutic area
Standard Dose
Once daily
Half-life
Plasma elimination
Route
Oral
Safety Tier
Limited data
Overview
Orforglipron is the answer to the question everyone's been asking about GLP-1 drugs: 'Can I just take a pill instead of injecting?' It's a small-molecule GLP-1 receptor agonist (not a peptide, technically) that you take orally once daily, unlike semaglutide or tirzepatide which require weekly injections. Phase 2 trials showed significant weight loss comparable to the injectables, which is why Eli Lilly is pushing it hard through development. The GI side effects are similar to other GLP-1 drugs, nausea, diarrhea, some vomiting, and they tend to be worst during the first few weeks as your body adjusts. It's still in clinical trials, so you won't find it at your pharmacy yet, but if it gets approved it could democratize GLP-1 therapy by removing the needle barrier. For now, this is one to watch rather than one to use.
Mechanism of Action
Orforglipron is the answer to the question everyone's been asking about GLP-1 drugs: 'Can I just take a pill instead of injecting?' It's a small-molecule GLP-1 receptor agonist (not a peptide, technically) that you take orally once daily, unlike semaglutide or tirzepatide which require weekly injections. Phase 2 trials showed significant weight loss comparable to the injectables, which is why Eli Lilly is pushing it hard through development. The GI side effects are similar to other GLP-1 drugs, nausea, diarrhea, some vomiting, and they tend to be worst during the first few weeks as your body adjusts. It's still in clinical trials, so you won't find it at your pharmacy yet, but if it gets approved it could democratize GLP-1 therapy by removing the needle barrier. For now, this is one to watch rather than one to use.
Benefits
- Oral administration
- Significant weight loss
- Improved glycemic control
- Convenient dosing
Side Effects
- GI side effects
- Nausea
- Diarrhea
- Headache
Contraindications
- Pregnant or breastfeeding women
- History of thyroid cancer
- Pancreatitis
Structure & Sequence
Verified structure
Orforglipron
Sequence illustration backed by PubChem match.
- Amino Acid Sequence
- Non-peptide small molecule GLP-1 receptor agonist
- Molecular Weight
- 883.0 Da
- Chemical Formula
- C48H48F2N10O5
- CAS Number
- N/A
- InChIKey
- USUWIEBBBWHKNI-KHIFEHGGSA-N
Stack & Route Context
Stacks with
No entries listed.
Administration
Oral
Research Status
Phase 2 clinical trials for obesity
Approval Status
Phase2
Sports Legal
Permitted
References
No references listed.
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.